lenalidomide,idecabtagene vicleucel
bms,2seventy bio
['bet', 'mmsm', 'ide-cel', 'karmma', 'karmma-2', 'bristol']
#ash22 awesome presentation by re: karmma-2a (ide-cel car-t for functional high-risk, i.e. early #mmsm relapse). median dor 16 mo. better than karmma-1 (4+ lines, mpfs 8.8mo) even given clear higher risk, likely since given earlier. bad news: still no plateau 
Asst Professor @UWMedicine @fredhutch, s/p @PennIMResidents ??@UCSFCancer training. Myeloma #MMsm #cellphonesandcelltherapies ????

COI: https://t.co/3Uuojuio6R